首页/数据集/Study evaluating, as first-line treatment of metastatic colorectal cancer, Bevacizumab +FOLFIRI followed by Bevacizumab + FOLFOX( or XELOX) or the reverse sequence Bevacizumab + FOLFOX (or XELOX) folloewed by Bevacizumab + FOLFIRI versus the standard Bevacizumab+ FOLFIRI

Study evaluating, as first-line treatment of metastatic colorectal cancer, Bevacizumab +FOLFIRI followed by Bevacizumab + FOLFOX( or XELOX) or the reverse sequence Bevacizumab + FOLFOX (or XELOX) folloewed by Bevacizumab + FOLFIRI versus the standard Bevacizumab+ FOLFIRI

NIAID Data Ecosystem2026-03-08 收录

转移性结直肠癌一线治疗

贝伐珠单抗联合化疗序贯研究

数据链接：

https://www.omicsdi.org/dataset/ecrin-mdr-crc/2532389 数据链接链接失效反馈

官方服务：

资源简介：

Primary objectives: Progression free survival

应用场景：

创建时间：

2014-03-15

转移性结直肠癌一线治疗

肿瘤药物临床试验

The purpose of this study is to determine the treatment effect of QL1203 in combination with mFOLFOX6 compared to Placebo in combination with mFOLFOX6 as first line therapy for metastatic colorectal c

NIAID Data Ecosystem80

First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer

转移性结直肠癌一线治疗

FOLFOXIRI联合贝伐珠单抗

This is a single-arm, open-label, multicentre phase II study evaluating the safety and efficacy of the combination of the G.O.N.O. FOLFOXIRI regimen with bevacizumab as first-line treatment of metasta

NIAID Data Ecosystem50

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF SUNITINIB IN METASTATIC COLORECTAL CANCER PATIENTS RECEIVING IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN (FOLFIRI) AS FIRST LINE TREATMENT

转移性结直肠癌一线治疗

舒尼替尼联合FOLFIRI方案

Primary objectives: To demonstrate that the combination of FOLFIRI plus sunitinib is superior to FOLFIRI plus placebo in prolonging the progression-free survival (PFS) in the first-line treatment of p

NIAID Data Ecosystem30

Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR).

转移性结直肠癌一线治疗

肿瘤血管

The PULSAR trial is an international, investigator-initiated, single arm open-label phase II study. The aim of this study is to measure the clinical activity of the combination FOLFIRI-aflibercept in

NIAID Data Ecosystem80

Capecitabine in combination with Oxaliplatin, Irinotecan and Bevacizumab (COI-B regimen) as First-Line therapy for metastatic colorectal cancer: a Phase II I.T.M.O. study.

转移性结直肠癌一线治疗

COI-B方案临床评价

Primary Objectives Determine the efficacy in terms of : Response rate Safety profile of the COI regimen when administered with bevacizumab Safety profile of bevacizumab when administered after the end

NIAID Data Ecosystem50

Study evaluating, as first-line treatment of metastatic colorectal cancer, Bevacizumab +FOLFIRI followed by Bevacizumab + FOLFOX( or XELOX) or the reverse sequence Bevacizumab + FOLFOX (or XELOX) folloewed by Bevacizumab + FOLFIRI versus the standard Bevacizumab+ FOLFIRI

资源简介：

相关数据集